pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,872 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1217Endpoints919BioPharma Dive354BioSpace340Fierce Biotech319onclive165raps111globenewswire health
therapy area
allOncology8285Rare Disease1943Cardiology1880Immunology1591Hematology1354Pulmonology1285Vaccines
  • Medline orders correction of convenience kits containing lidocaine and bupivacaine in dextrose injection
    Medline has issued a correction for certain convenience kits that include lidocaine hydrochloride and bupivacaine hydrochloride mixed with dextrose injection. The FDA has classified this recall as…
    fda medwatch · 1mo agoCRLNegative↗ source
  • American Regent recalls two lots of Adequan canine injection and two lots of Adequan i.m. for horses due to glass fibers
    American Regent Animal Health announced a nationwide recall of specific lots of its Adequan products for dogs and horses. The recall includes two lots of the 100 mg/mL 5 mL multi‑dose canine injec…
    fda medwatch · 1mo agoCRLNegative
← prev
page 42 of 115
next →
73
fda recalls71
fda medwatch63
fda press38
1279
Psychiatry & CNS895
Ophthalmology521
Pain503
Endocrinology & Metabolism496
Infectious Disease459
↗ source
  • HHS Secretary RFK Jr. defends Trump admin, critiques vaccine research while endorsing measles vaccine
    HHS Secretary Robert F. Kennedy Jr. gave an interview on August 3, 2026 in which he reiterated his support for the Trump administration and voiced criticism of current vaccine research practices.…
    Endpoints · 1mo agoNeutral↗ source
  • New York Senate advances assisted-dying bill as Nebraska Medicaid work rules spark coverage losses
    The New York Senate moved forward with legislation that would allow assisted dying, marking a significant step toward legalizing the practice in the state. In Nebraska, the recent implementation o…
    STAT · 1mo agoNeutral↗ source
  • After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
    One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
    Fierce Biotech · 1mo agoNeutral↗ source
  • Nominations Open for 2026 Fiercest Women in Life Sciences, Deadline Sept 18
    Nominations are now open for the 2026 Fiercest Women in Life Sciences, an annual report that spotlights women making significant contributions across pharma, biotech, medtech, academia, venture cap…
    Fierce Biotech · 1mo agoPositive↗ source
  • Neurologist Who Diagnoses ALS Patients Receives Own Diagnosis, Reflects on Impact of Disability
    Dr. Christopher Campos, a neurologist and assistant professor at UC Davis Health, disclosed that he was diagnosed with amyotrophic lateral sclerosis (ALS) in 2025 after a decade of delivering the s…
    STAT · 1mo agoNegative↗ source
  • AstraZeneca and Bristol Myers Squibb reportedly in talks on a mega merger
    AstraZeneca is said to be discussing a possible merger with Bristol Myers Squibb, according to a Financial Times report published on Sunday. The combination would rank among the largest consolidat…
    Endpoints · 1mo agoDealNeutral↗ source
  • Michigan Supreme Court permits state probe into Eli Lilly insulin pricing
    A divided Michigan Supreme Court on Friday ruled that the state attorney general can move forward with an investigation into Eli Lilly’s insulin pricing. The 4-to-3 decision overturned a lower-cou…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Senate stopgap bill temporarily blocks White House plan to politicize federal research grants
    Senate leadership released text of a bipartisan continuing resolution that would fund the government through Dec. 11 and include a provision blocking the White House's proposal to place political a…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Alnylam’s stock continues to fall as weekly roundup highlights Q2 earnings across biopharma
    The August 1 edition of Endpoints Weekly opens with a look at the latest biopharma earnings season. Alnylam Therapeutics is highlighted for a continued decline in its share price, reflecting ongoi…
    Endpoints · 1mo agoEarningsNegative↗ source
  • Novo Nordisk's heart drug ziltivekimab fails Phase 3 trial, raising doubts on inflammation-targeted therapies
    Novo Nordisk announced that its experimental cardiovascular drug ziltivekimab did not meet the primary endpoint in a Phase 3 study. The trial was designed to see if the drug could lower the inciden…
    BioPharma Dive · 1mo agoNegative readoutNegative↗ source
  • Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trial
    Novo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • ResMed issues correction for Astral ventilators due to electrical component failure risk
    ResMed has released a correction for certain Astral ventilators after identifying a faulty electrical component that could interrupt therapy and cause serious injury or death. The FDA classifies t…
    fda medwatch · 1mo agoRegulatoryNegative↗ source
  • Resilience and Eli Lilly commit $750 million to expand Cincinnati GLP-1 injectable production
    Resilience and Eli Lilly announced a joint $750 million investment to expand drug manufacturing capacity in Cincinnati. The expansion will add at least 400 jobs and increase Resilience's workforce…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trial
    Novo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study. The trial enrolled…
    STAT · 1mo agoNegative readoutNegative↗ source
  • Madrigal spends $255 million on multiple MASH drug deals to complement Rezdiffra
    Madrigal Pharmaceuticals is expanding its MASH pipeline by acquiring several assets that could be used alongside its lead candidate, Rezdiffra. In early 2026 the company paid $50 million to Pfizer…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD program
    Novo Nordisk reported that its phase 3 Zeus trial of the IL‑6 ligand antibody ziltivekimab did not meet its primary endpoint, a setback for the drug's development. The study enrolled more than 6,3…
    Fierce Biotech · 1mo agoNegative readoutNegative↗ source
  • Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drug
    Apnimed, a Massachusetts‑based biotech, announced an upsized initial public offering that now includes 12 million shares priced at $16 each, generating $192 million in gross proceeds. This amount e…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Abiomed recalls 14Fr Low Profile Introducer Kits over thrombus risk
    The FDA has issued an early alert about a recall of Abiomed 14Fr Low Profile Introducer kits, which are used with Impella CP devices. The recall follows a higher‑than‑expected rate of complaints i…
    fda medwatch · 1mo agoCRLNegative↗ source
  • AbbVie says Skyrizi maintains strong sales momentum as competition rises
    AbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…
    Endpoints · 1mo agoPositive↗ source
  • Pharma groups support revised 340B rebate pilot that permits limited rebate denials
    Health Resources and Services Administration (HRSA) announced details of a revised 340B rebate pilot. The new rules would let drug manufacturers refuse rebates on a limited set of drugs, a shift fr…
    Endpoints · 1mo agoRegulatoryPositive↗ source
  • Sanofi CEO pledges to rebuild trust and expand partnership with Regeneron
    Sanofi's new chief executive, Belén Garijo, told analysts that restoring the relationship with longtime partner Regeneron is a top priority. She said the company wants to be more transparent and to…
    BioPharma Dive · 1mo agoNeutral↗ source
  • Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPO
    Ratio Therapeutics, a Boston-based biotech, announced a $70 million Series C financing to fund its radiopharmaceutical development program. The round was led by existing backers Duquesne Family Of…
    Endpoints · 1mo agoDealPositive↗ source
  • FDA advisory panel backs experimental Replimune melanoma therapy after two prior rejections
    An FDA advisory committee voted 10‑to‑3 to recommend the use of an experimental Replimune treatment for patients with advanced melanoma. The panel’s recommendation marks a shift after the agency p…
    STAT · 1mo agoPositive readoutPositive↗ source